

## Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells

Darja Karpova, ... , Daniel C. Link, John F. DiPersio

*J Clin Invest.* 2019. <https://doi.org/10.1172/JCI124738>.

**Research** In-Press Preview

Mobilized peripheral blood has become the primary source of hematopoietic stem and progenitor cells (HSPCs) for stem cell transplantation, with a five-day course of granulocyte colony stimulating factor (G-CSF) as the most common regimen used for HSPC mobilization. The CXCR4 inhibitor, plerixafor, is a more rapid mobilizer, yet not potent enough when used as a single agent, thus emphasizing the need for faster acting agents with more predictable mobilization responses and fewer side effects. We sought to improve hematopoietic stem cell transplantation by developing a new mobilization strategy in mice through combined targeting of the chemokine receptor CXCR2 and the very late antigen 4 (VLA4) integrin. Rapid and synergistic mobilization of HSPCs along with an enhanced recruitment of true HSCs was achieved when a CXCR2 agonist was co-administered in conjunction with a VLA4 inhibitor. Mechanistic studies revealed involvement of CXCR2 expressed on BM stroma in addition to stimulation of the receptor on granulocytes in the regulation of HSPC localization and egress. Given the rapid kinetics and potency of HSPC mobilization provided by the VLA4 inhibitor and CXCR2 agonist combination in mice compared to currently approved HSPC mobilization methods, it represents an exciting potential strategy for clinical development in the future.

**Find the latest version:**

<https://jci.me/124738/pdf>



# Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells

Darja Karpova<sup>1,2\*</sup>, Michael P. Rettig<sup>1\*</sup>, Julie Ritchey<sup>1</sup>, Daniel Cancilla<sup>1</sup>, Stephanie Christ<sup>1</sup>, Leah Gehrs<sup>1</sup>, Ezhilarasi Chendamarai<sup>1</sup>, Moses O. Evbuomwan<sup>3</sup>, Matthew Holt<sup>1</sup>, Jingzhu Zhang<sup>1</sup>, Grazia Abou-Ezzi<sup>1</sup>, Hamza Celik<sup>1</sup>, Eliza Wiercinska<sup>4</sup>, Wei Yang<sup>5</sup>, Feng Gao<sup>6</sup>, Linda G. Eissenberg<sup>1</sup>, Richard F. Heier<sup>7,8</sup>, Stacy D. Arnett<sup>7,8</sup>, Marvin J. Meyers<sup>7,9</sup>, Michael J. Prinsen<sup>7,10</sup>, David W. Griggs<sup>7,11</sup>, Andreas Trumpp<sup>2</sup>, Peter G. Ruminski<sup>1,7</sup>, Dwight M. Morrow<sup>12</sup>, Halvard B. Bonig<sup>4,13</sup>, Daniel C. Link<sup>1</sup> and John F. DiPersio<sup>1</sup>

<sup>1</sup> Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA

<sup>2</sup> Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany

<sup>3</sup> Oakland University William Beaumont School of Medicine, Rochester, MI, USA

<sup>4</sup> German Red Cross Blood Service and Institute for Transfusion Medicine and Immunohematology of the Goethe University, Frankfurt, Germany

<sup>5</sup> Genome Technology Access Center, Washington University, St. Louis, MO, USA

<sup>6</sup> Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA

<sup>7</sup> Center for World Health and Medicine, Saint Louis University, St. Louis, MO, USA

<sup>8</sup> Current address: Confluence Discovery Technologies, St. Louis, MO, USA

<sup>9</sup> Current address: Department of Chemistry, Saint Louis University, St. Louis, MO, USA

<sup>10</sup> Current address: HTS Robotics Core, Washington University School of Medicine, St. Louis, MO, USA

<sup>11</sup> Current address: Department of Molecular Microbiology & Immunology, Saint Louis University School of Medicine, St. Louis, MO, USA

<sup>12</sup> Magenta Therapeutics, Cambridge, MA, USA

<sup>13</sup> University of Washington, Dept. of Medicine/Hematology, Seattle, WA

\* **Authorship note:** DK and MR contributed equally to this work

**Corresponding author:** John F. DiPersio, MD, PhD

Division of Oncology

Washington University School of Medicine

660 S. Euclid Ave., Campus Box 8007

St. Louis, Missouri, USA, 63110

Email: [jdipersi@wustl.edu](mailto:jdipersi@wustl.edu)

**Conflict of interest:** DK and JFD have a patent application (PCT/US2017/059770, compositions comprising integrin inhibitors and agents that interact with a chemokine receptor). PGR, MJM, RFH, MPR, and JFD have pending applications (PCT/US2017/059777; Integrin inhibitors and chemokine receptor agents, and PCT/US2017/059733 Integrin Antagonists) and report royalties received from it during the conduct of the study. PGR, MJM, RFH, MPR, DWG, and JFD have 1 or more additional patents unrelated to the topic of this work that are listed in an appendix in the supplement. JFD has a first-tier potential conflict due to equity ownership in Magenta Therapeutics and WUGEN Inc. JFD is founder and advisor for Magenta Therapeutics Inc. and WUGEN Inc; receives income from RiverVest Venture Partners and Magenta Therapeutics; receives and/or received during the study period research funding from Amphivena Therapeutics, NeoimmuneTech Inc, MacroGenics Inc, Incyte Corp., BiolineRx, Altiris, and WUGEN Inc.; is an Advisory Board Member for Cellworks Group, RiverVest Venture Partners, and Arch Oncology. DMM is an employee of and owns equity in Magenta Therapeutics. PGR has stock in Pfizer Inc. PGR and DWG are co-founders of, consultants for, and own equity in Indalo Therapeutics, a company pursuing clinical development of RGD-binding integrin antagonists, but not of antagonists of a  $\alpha 4\beta 1$  (VLA4). MPR serves as a consultant for RiverVest Venture

Partners, receives research funding from Amphivena Therapeutics and received research funding from Novimmune and Cantex during the study. MJM also has research funding from Ultragenyx Pharmaceutical Inc and is the founder and owner of Meyers MedChem Consulting LLC. RFH is currently an employee of Confluence Discovery Technologies. LE received research funding from MaxCyte Inc. during the study. HBB is a co-inventor of patent PCT/EP2015/066083 from which he receives royalties and licensing fees; has received honoraria from Miltenyi, Celgene, Sandoz-Hexal, Novartis, Terumo BCT; received research support from Sandoz-Hexal, Amgen, Polyphor, Stage (now Juno), Miltenyi, Terumo BCT; served on advisory boards of Genzyme, Novartis, Celgene, Terumo BCT. None of these are related to the work presented here.

## **Abstract**

Mobilized peripheral blood has become the primary source of hematopoietic stem and progenitor cells (HSPCs) for stem cell transplantation, with a five-day course of granulocyte colony stimulating factor (G-CSF) as the most common regimen used for HSPC mobilization. The CXCR4 inhibitor, plerixafor, is a more rapid mobilizer, yet not potent enough when used as a single agent, thus emphasizing the need for faster acting agents with more predictable mobilization responses and fewer side effects. We sought to improve hematopoietic stem cell transplantation by developing a new mobilization strategy in mice through combined targeting of the chemokine receptor CXCR2 and the very late antigen 4 (VLA4) integrin. Rapid and synergistic mobilization of HSPCs along with an enhanced recruitment of true HSCs was achieved when a CXCR2 agonist was co-administered in conjunction with a VLA4 inhibitor. Mechanistic studies revealed involvement of CXCR2 expressed on BM stroma in addition to stimulation of the receptor on granulocytes in the regulation of HSPC localization and egress. Given the rapid kinetics and potency of HSPC mobilization provided by the VLA4 inhibitor and CXCR2 agonist combination in mice compared to currently approved HSPC mobilization methods, it represents an exciting potential strategy for clinical development in the future.

## Introduction

In post-natal mammals, the vast majority of hematopoietic stem and progenitor cells (HSPC) reside in the protective environment of the bone marrow (BM) (1, 2). Accordingly, only very few HSPCs can be found in the periphery, primarily in blood and spleen, during homeostasis (3). A wide variety of stimuli have been identified that elicit HSPC egress from the marrow, a phenomenon referred to as mobilization (4). Despite its significance and the preclinical discovery of various approaches to lure HSPC into the circulation during the past two decades, the armamentarium of clinical mobilization remains sparse. Thus, granulocyte colony stimulating factor (G-CSF) is the sole agent approved for mobilization of healthy donors, whereas in patients chemotherapy and the small molecule antagonist of the chemokine receptor CXCR4, AMD3100 (Plerixafor), are approved in conjunction with G-CSF (5).

Limitations of currently available clinical regimens provide the rationale for the ongoing search for alternative mobilization strategies. Importantly, all approaches described to date target at least one of the two major axes mediating HSPC retention: the chemokine receptor CXCR4 or the integrin very late antigen 4 (VLA4) (4, 6, 7). Inhibition of the interaction between CXCR4 and its chief ligand CXCL12 has been extensively studied by us and others (8-13). By contrast, targeting of VLA4 and use thereof to release HSPCs from the BM has been explored considerably less intensively due to lack of suitable small molecule compounds with favorable pharmacologic properties (7, 14).

The chemokine receptor CXCR2 is a critical regulator of neutrophil chemotaxis (15). Interestingly, stimulation of CXCR2 signaling (e.g. with its ligands CXCL1, -2 or -8) has been demonstrated to result in rapid HSPC mobilization from the BM even though the receptor is not expressed on HSPCs themselves (16-20). The mechanism of HSPC egress after CXCR2 stimulation remains controversial.

In this study, we explored the potential of combined targeting of VLA4 and CXCR2 signaling as a novel strategy to mobilize HSPCs. In addition to being associated with a rapid and remarkably synergistic HSPC release, administration of a VLA4 antagonist in conjunction with a CXCR2 ligand targeted very primitive, serially repopulating HSPCs with high efficiency. Our observations challenge

the notion of limited potential of fast-acting mobilizing agents and are particularly relevant in the context of the ongoing debate about the vascular vs. endosteal localization of stem cells (21-23). Moreover, unexpectedly, stromal cells were found to be targeted by CXCR2 stimulation along with neutrophils. This contribution of both stromal and neutrophilic CXCR2 to the regulation of HSPC localization underlies the intricate interplay between non-hematopoietic and mature hematopoietic cells for HSPC maintenance.

## Results

### Combined targeting of VLA4 and CXCR2 results in augmented HSPC recruitment

We assessed the mobilization efficiency of a VLA4 antagonist alone compared to a CXCR2 agonist alone as well as their combined effect in vivo. The previously described small molecule VLA4 inhibitor fimategrast (24, 25) along with the naturally occurring truncated form of the CXCR2 ligand Gro- $\beta$  (tGro- $\beta$ ) (26, 27) were used in the initial experiment. As shown in Figure 1, combined treatment with both agents resulted in increased numbers of circulating WBC and CFU-C of up to 3- and 10-fold respectively (Figure 1A and B). To circumvent the shortcomings of VLA4 targeting compounds hitherto tested as mobilizing agents, we selected a series of VLA4 antagonists that had been developed based on the structure of the well-known VLA4 inhibitors BIO5192(28) and fimategrast (24, 25). These compounds (CWHM-822, 823, 824, 825 and 842; Figure 1C) were synthesized as previously described (29-34). Properties of the inhibitors were assessed using a colorimetric, cell-free solid phase receptor binding assay (SPRA, Suppl. Table 1) as well as a flow cytometry-based soluble VCAM1 binding assay (Figure 1D). CWHM-823, -824 and -842 showed superior binding affinity to VLA4 compared to Fimategrast (Figure 1D). CWHM-822 and 823 had an improved water solubility compared to both BIO5192 and fimategrast (Suppl. Table 1).

We next tested whether the synergism between VLA4 inhibition and CXCR2 stimulation was a compound class as opposed to a compound-specific effect. Therefore, mobilization with BIO5192 and Fimategrast was tested alongside the new compounds, CWHM-823 and -842. All four inhibitors mobilized HPSC by themselves, whereas the mobilization response was enhanced up to 3-10-fold when combined with tGro- $\beta$  (Figure 1E), suggesting a compound class specific effect. Fimategrast-related CWHM-823 outperformed the BIO5192-related CWHM-842 in vivo and was therefore selected for the majority of our subsequent analyses. Optimal pharmacokinetics and pharmacodynamics were determined to be associated with subcutaneous administration of the CWHM-823 + tGro- $\beta$  mixture (Suppl. Figure 1A-B). Time and dose-response analysis revealed no increase in mobilization between 3

and 15 mg/kg of CWHM-823 while peak mobilization was reached approx. 30 minutes after the injection (Suppl. Figure 1C).

Complementary to the testing of different VLA4 inhibitors, stimulation with tGro- $\beta$  (CXCL2) was compared to that with the alternative CXCR2 ligands CXCL1 (Gro- $\alpha$ ) and CXCL8 (IL-8). Again, all three agonists induced HSPC mobilization when given alone as well as in combination with CWHM-823 (Figure 1F). To control for specificity of the observed effects, CXCR2 KO mice were included. As expected, CXCR2 ligands alone did not induce mobilization in CXCR2 KO mice. Mobilization with the VLA4 antagonist was higher in absolute numbers yet qualitatively unchanged considering the higher baseline levels of circulating CFU-C (930 CFU-C/ml (BALB/cJ CXCR2 KO) vs. 300 CFU/ml (BALB/cJ WT) at baseline / 3800 CFU-C/ml (BALB/cJ CXCR2 KO) vs. 1300 CFU-C/ml (BALB/cJ WT) mobilized with CWHM-823). Surprisingly, a decrease in mobilization with CWHM-823 was observed in CXCR2 knockout mice when CXCR2 ligands were co-administered with the VLA4 antagonist. One possible explanation for this is that the bioavailability of CWHM-823 is reduced upon administration in conjunction with the chemokine alone as compared to when it is administered alone (Suppl. Figure 1B). Lack of specificity for the target receptor CXCR2 appears unlikely: in our comprehensive screening of tGro- $\beta$  against a panel of 348 different G-Protein coupled receptors no cross-reactivity of the chemokine with any receptors other than CXCR2 was found (Suppl. Table 2).

### **Properties of mobilized cells**

Having established that VLA4 inhibition combined with CXCR2 stimulation achieves superior CFU-C mobilization, we compared the repopulating capacity of the grafts mobilized with this new regimen, the single agents, or G-CSF (Figure 2A). For both VLA4 antagonists tested, firsategrast and CWHM-823, significantly increased blood graft-derived contribution in the primary recipients was detected when combined with tGro- $\beta$  compared to engraftment from blood mobilized by either of the VLA4 antagonists or tGro- $\beta$  alone (Figure 2B). More importantly, despite higher numbers of CFU-C mobilized by G-CSF (Suppl. Figure 2 and data not shown), the concentration of repopulating units in

the blood of mice mobilized with VLA4 antagonist + tGro- $\beta$  was equal to that of G-CSF. Analysis of secondary recipients i.e. evidence of serially repopulating units, confirmed virtually identical mobilization potency within the immature HSC fraction for G-CSF and VLA4 antagonist + tGro- $\beta$  (Figure 2C). Moreover, in a model of diabetes-associated poor mobilization (10, 35, 36), generated by exposure of mice to the pancreas toxic agent streptozotocin, mobilization was better preserved with VLA4 antagonist+tGro- $\beta$  combination as compared to G-CSF (7200 CFU-C/ml in diabetic compared to 22200 CFU-C/ml in healthy mice with G-CSF; 9000 compared to 6350 CFU-C/ml with CWHM-823+ tGro- $\beta$ , Suppl. Figure 2).

We then performed gene expression profiling of differentially mobilized HSPC. LSK cells isolated from the blood of mice treated with AMD3100 (1 hr), G-CSF (5 days) or CWHM-823 + tGro- $\beta$  (30 min) along with LSK cells from BM of untreated mice were examined using microarray analysis. A high degree of similarity between the analyzed LSK types was found, with AMD3100 mobilized LSK being the only group clustering somewhat separately from the other three using principal component analysis (PCA, Figure 2D). In comparison to BM, LSK cells mobilized by CWHM-823 + tGro- $\beta$  had only 45 genes with significantly different expression levels (Suppl. Table 3). CWHM-823 + tGro- $\beta$  versus G-CSF had only 53 such genes (Suppl. Table 4). By contrast 694 genes were significantly up- or down-regulated between AMD3100 and CWHM-823 + tGro- $\beta$  mobilized LSK cells despite their very similar kinetics of mobilization (Suppl. Table 5). The close relationship between CWHM-823 + tGro- $\beta$  mobilized LSK, BM-resident LSK and G-CSF LSK was further evident upon clustering of the top 1000 differentially expressed genes which demonstrated clear separation of the AMD3100 mobilized LSK (Figure 2E).

Among the genes significantly enriched in CWHM-823 + tGro- $\beta$  mobilized LSK the transcription factors Nr4A1-3 were identified (Figure 2F). Members of this nuclear receptor family have previously been shown to specify a population of myeloid-biased long-term repopulating HSCs (37). This is consistent with a relative enrichment of the latter within CWHM-823 + tGro- $\beta$  targeted HSPCs. Distinct properties of CWHM-823 + tGro- $\beta$  LSK cells were further confirmed when cell cycle status of differentially mobilized HSPC was assessed (Suppl. Figure 3). LSK cells mobilized with CWHM-823 were

predominantly quiescent with > 70% found in the G<sub>0</sub> phase and approximately 25 % and 3 % in G<sub>1</sub> and G<sub>2</sub>/S/M phases of the cell cycle, respectively. A much lower proportion of tGro-β mobilized LSKs were not cycling (approx. 50% in G<sub>0</sub>) and virtually no cells were in G<sub>2</sub>/S/M phase. In contrast, more than half of the LSKs from CWHM-823 + tGro-β mobilized blood were actively cycling and 5 % were found in the G<sub>2</sub>/S/M phase. Thus, LSK cells mobilized with the combination of VLA4 inhibition and CXCR2 stimulation do not simply represent a mix of those mobilized by single agents. Given the rapid kinetics of mobilization by these agents when administered alone and in combination, the discrepancies between the cell cycle distribution imply preferential targeting of distinct LSK species rather than changes induced upon exposure to the different agents.

### **Cellular mechanism of mobilization**

We sought to determine which of the two events, CXCR2 stimulation or VLA4 inhibition, needs to occur first and is therefore priming for the subsequent response to the second stimulus. Pretreatment with the VLA4 antagonist (CWHM-823, 45 min prior to tGro-β administration) did not alter subsequent tGro-β induced mobilization (Figure 3A). In contrast, albeit lower than when both compounds were given simultaneously, significantly elevated numbers of circulating CFU-C were detected in CWHM-823 mobilized mice that had been pretreated with tGro-β as compared to PBS. These findings pointed towards CXCR2 targeting as the “priming” event of the two.

Within the hematopoietic compartment CXCR2 expression was detected almost exclusively in granulocytes, and specifically HSCs themselves were CXCR2-negative (Suppl. Figure 4). Therefore, as expected, when granulocytes were depleted from the circulation (Figure 3B and C), mobilization response to tGro-β alone as well as to the combination of CWHM-823 + tGro-β were completely blunted (Figure 3D).

In order to distinguish between hematopoietic-intrinsic vs. non-hematopoietic contributions for mobilization with CWHM-823 + tGro-β, chimeric animals were generated by transplanting CXCR2 KO or WT BM cells into wildtype recipients and *vice versa*, WT cells into CXCR2 KO or WT recipients

(Figure 4A). Following reconstitution mice were mobilized with CWHM-823 alone, tGro- $\beta$  alone, or the combination. As expected, mobilization with the VLA4 antagonist alone was similar in both hematopoietic and stromal CXCR2 knockouts (Figure 4B). No HSPC mobilization with tGro- $\beta$  alone was observed in WT recipients reconstituted with CXCR2 KO BM (Figure 4C, first and second bar from left). Surprisingly, CXCR2 knockout recipients engrafted with the wild type BM also demonstrated attenuated mobilization (Figure 4C, fifth and sixth bar from left) indicating an additional contribution of non-hematopoietic (stromal) CXCR2 to the tGro- $\beta$  induced HSPC egress. Moreover, the combination of CWHM-823 + tGro- $\beta$  mobilized HSPC with almost equal potency in WT recipients of CXCR2 knockout and WT BM (Figure 4D, comparing second and fourth bar from left). Mobilization of similar magnitude was also detected in CXCR2 knockout and WT recipients reconstituted with WT BM. Stimulation of either hematopoietic or stromal CXCR2 was therefore sufficient to elicit synergistic mobilization when combined with inhibition of VLA4 signaling.

Expression and functional role of CXCR2 in endothelial cells (EC) has been described (38, 39). Our previous studies indicated absence of CXCR2 expression in CXCL12 abundant reticular cells (CAR; (40), another major cellular player involved in HSPC retention (41)). We therefore tested whether CXCR2 ablation restricted to endothelial cells would lead to changes in mobilization responses. As shown in Figure 4E, mobilization with all three regimens (CWHM-823, tGro- $\beta$  and CWHM-823+tGro- $\beta$ ) was decreased in CXCR2 EC KO recipients compared to the control group. Most pronounced was the effect observed with tGro- $\beta$  alone.

#### **Role of cellular adhesion:**

Our studies in Figure 4 suggested that stimulation of CXCR2 on either granulocytes or stroma was sufficient to recruit as many HSPC into the circulation as when the target receptor was present in both compartments. This led us to investigate the role of adhesive cross-stimulatory interaction between neutrophils and stroma, likely initiated through exposure to the chemokine. Beta 2 integrins, LFA1 (ITGAL/ITGB2, CD11a/CD18) and Mac1 (ITGAM/ITGB2, CD11b/CD18) are well-known, crucial

mediators of neutrophil adhesion to vasculature(42, 43). Both have been shown to become activated after CXCR2 stimulation(44-46) and have been previously implicated in CXCR2 and G-CSF triggered mobilization (19, 47, 48).

At baseline, no significant hematological changes were found in mice lacking LFA1 (CD11a KO) or Mac1 (CD11b KO) except for a slight increase in circulating neutrophils in CD11a knockouts (Figure 5A-C). Mobilization of CFU-C with CWHM-823 was approximately doubled in CD11a or CD11b deficient mice, whereas both strains' response to tGro- $\beta$  alone was the same as in WT mice despite a dramatic neutrophilia induced in the CD11a KO mice in response to tGro- $\beta$  (Figure 5B). The response to the combination treatment was significantly attenuated (Figure 5C).

#### **Role of Proteases:**

Considering the fact that CXCR2 is not expressed on the surface of the HSPCs themselves, we next addressed the question of the molecular crosstalk initiated by CXCR2 stimulation and how it enables HSPC egress. Previous reports aiming to elucidate the mechanism of tGro- $\beta$  and AMD3100 + tGro- $\beta$  induced-HSPC release suggested critical involvement of the matrix metalloprotease 9 (MMP9) (49-52). Therefore, we compared mobilization with the combination of CWHM-823 + tGro- $\beta$  against AMD3100+tGro- $\beta$  as well as single agent treatments in MMP9 knockout mice on both FVB and C57BL/6 (B6) background (Suppl. Figure 5A-B). In addition, a pharmacologic model in the form of a broad-spectrum MMP inhibitor, Batimastat, was employed (Suppl. Figure 5C). Baseline circulating HSPC numbers or AMD3100 induced mobilization were not affected by the genetic MMP9 deficiency or by the MMP blockade. CWHM-823-induced mobilization was equally potent in FVB wildtype and FVB MMP9 KO mice and was not affected by Batimastat. However, mobilization was stronger in B6 MMP9 knockout mice than in their wild type counterparts. Conversely, tGro- $\beta$ - and AMD3100 + tGro- $\beta$ -induced mobilization was significantly reduced in FVB MMP9 KO mice or following MMP inhibitor treatment, but it was not altered in B6 MMP9 knockouts. Interestingly, the combination of CWHM-823 + tGro- $\beta$  mobilized with equal efficiency in both knockout strains relative to wildtype control mice,

while mobilization was slightly, but not significantly, reduced in mice pretreated with Batimastat. Taken together these data do not support a clear role of MMP9 in CWHM-823 + tGro- $\beta$  associated augmented mobilization. Rather, they suggest differences in the mechanism underlying mobilization induced by combining CXCR2 stimulation and VLA4 blockade compared to CXCR2 activation in conjunction with CXCR4 blockade.

## Discussion

In the current study a novel mobilization strategy, CXCR2 stimulation combined with inhibition of the VLA4 integrin, was investigated and found to result in a rapid, synergistic and highly efficient recruitment of HSPCs into the circulation. Implementation of VLA4 antagonists with improved properties allowed for comprehensive testing and optimization of mobilization achieved through VLA4 targeting. This revealed VLA4 as a promising target associated with mobilization of a clinically relevant magnitude. Compared to mobilization with G-CSF, long-term serially repopulating HSCs were relatively more strongly enriched in VLA4 inhibitor + CXCR2 agonist mobilized grafts than clonogenic cells without long-term repopulating capacity, indicating preferential targeting of a very immature HSPC fraction. Given how brisk the mobilization occurred and assuming BM sinusoids as the exit route for HSCs, our findings support the notion of a close proximity of the mobilization-sensitive HSC to BM sinusoids. Moreover, the numbers of rapidly mobilizable HSC markedly exceed previous estimates. Furthermore, we found an unexpected contribution of stromal (endothelial) CXCR2 to the mobilization induced by tGro- $\beta$  alone as well as by VLA4-antagonist + tGro- $\beta$ , hinting at a previously unsuspected crosstalk between granulocytes and stroma as a master regulator of HSPC localization and egress.

The cytokine G-CSF and chemotherapy triggered myeloid rebound, the two commonly utilized clinical mobilization regimens, are comprised of two partly overlapping steps, proliferation and the actual release of the HSPC from the BM (53, 54). Although not necessary nor sufficient for mobilization per se, proliferation (and therefore expansion) of HSPCs clearly contributes to the magnitude of G-CSF and chemotherapy induced HSPC mobilization (55). In addition to the obvious increase in numbers, HSPC localization has been reported to change over the course of proliferation favoring closer proximity to the vessels, which in turn facilitates BM exit (56, 57). In comparison, the rapid kinetics of mobilization with VLA4-antagonist + tGro- $\beta$  (peak reached within 15-30 minutes of s.c. injection) would not allow for cell division to occur prior to the HSPC release from the BM. Therefore, the relative enrichment for primitive, serially repopulating units in the VLA4-antagonist + tGro- $\beta$  mobilized blood grafts likely reflects their preferential targeting and a preferential vascular (sinusoidal) localization.

Compared to G-CSF and chemotherapy, much less severe alterations in the BM composition in the course of VLA4-antagonist + tGro- $\beta$  mediated mobilization are to be expected, which is particularly important in light of the very similar potency.

Mature hematopoietic cells contained in the transplant have been shown to directly influence HSPC engraftment. For example, the presence of regulatory T cells was demonstrated to ensure HSPC survival and colonization of the host BM (58). Also, bystander effects of the myeloid compartment, granulocytes in particular, for the establishment of the niche following irradiation/transplantation were described recently (59). Thus, granulocyte derived TNF $\alpha$  was shown to facilitate vasculogenesis, a critical step during regeneration. Given the high percentage as well as the direct stimulation of neutrophils in VLA4-antagonist + tGro- $\beta$  (and also G-CSF) mobilized blood specimens, it is conceivable that granulocyte derived factors contribute to the superior performance of the corresponding grafts. While not excluding this possibility, the results of our LSK gene expression profiling further imply inherent differences in the profile and composition of the differentially mobilized vs. BM resident HSPC populations themselves. In line with the idea that differences within the HSPC fraction (i.e., a higher proportion of more immature, serially repopulating cells) are primarily responsible for the observed graft fitness, LSK SLAM cells purified from AMD3100 + tGro- $\beta$  mobilized blood (a regimen very similar to ours) were found to outperform those isolated from G-CSF treated blood donors when both were tested head-to-head in a competitive transplant assay against BM cells (52).

Neutrophils have been demonstrated to be indispensable for IL-8 (and G-CSF) induced mobilization (51, 60). Therefore, our observation of a significant reduction of tGro- $\beta$  as well as CWHM-823 + tGro- $\beta$  associated mobilization in the context of granulocyte deficiency was in line with expectations. By contrast, the subsequent findings that non-hematopoietic CXCR2 expressing cells co-regulate HSPC egress triggered by tGro- $\beta$  alone and that the presence of the receptor in either one of the compartments, stroma or hematopoietic cells, was in fact sufficient to elicit HSPC egress when the combination of CWHM-823 + tGro- $\beta$  was used, were very much surprising. Thus, while the presence of granulocytes was necessary for both, tGro- $\beta$  and CWHM-823 + tGro- $\beta$  induced mobilization, lack of

CXCR2 expression on their surface seemed, to a large extent, to be compensated for in the case of CWHM-823 + tGro- $\beta$  treatment, as long as the stromal CXCR2 was present.

Relevant for the interactions between HSPC and neutrophils, a role of CXCR2 expression in endothelia has been increasingly recognized. Accordingly, CXCR2 expression in endothelial cells of the lung vessels and its involvement in controlling neutrophil passage from the circulation into the lung parenchyma has been described (38). CXCR2 signaling has also been shown to critically mediate endothelial cell proliferation and therefore vascular repair post-transplant (39). Moreover, involvement of the zebrafish CXCR2 orthologue CXCR1 in the hematopoietic stem cell niche remodeling during embryogenesis has been demonstrated (61). Our findings along with the results of a companion study (Zhang, J and Link, DC, unpublished observations) imply an additional, immediate role of endothelial CXCR2 in the regulation of HSPC retention vs. egress.

Significant controversy surrounds the role of matrix metalloproteases in general and MMP9 in particular for mobilization regimens involving neutrophil stimulation such as tGro- $\beta$ , IL-8, or G-CSF. In a recent study by Hoggatt et al. describing a mobilization approach similar to ours (AMD3100 + tGro- $\beta$  (52)) the authors reported a contribution of MMP9 activity to the synergistic mobilization response in mice. Moreover, a correlation between mobilization efficiency in healthy G-CSF donors and activity of the MMP9 inhibitor TIMP1 was described. In our analysis, a trend towards more pronounced contribution of MMP9 during AMD3100 + tGro- $\beta$  as compared to CWHM-823 + tGro- $\beta$  induced HSPC egress was observed. However, a requirement for intact MMP9 for tGro- $\beta$  based regimen could not be corroborated.

The differences in the magnitude and kinetics of HSPC egress associated with the different regimens analyzed in this study, as well as the distinct properties of cells mobilized with VLA4 antagonists alone vs. tGro- $\beta$  alone vs. VLA4 antagonist + tGro- $\beta$ , can be interpreted as a result of targeting distinct HSPC subsets (Figure 6). Thus, based on their performance in the competitive transplantation setting (Figure 2A-C), more mature progenitor cells are primarily mobilized with a VLA4 antagonist alone (Figure 6B). Expression of the beta 2 integrins LFA1 and Mac1 on human and murine

progenitor cells (HPCs) but not stem cells has been demonstrated (48, 62). Hence, although not significantly dislodging stem cells when blocked individually, inhibition of LFA1 or Mac1 in conjunction with VLA4 blockade resulted in enhanced HPC mobilization. Consistent with the direct mode of action of VLA4 antagonists (4, 63), loss of granulocytes did not affect VLA4 inhibitor induced HSPC egress.

Peak mobilization after tGro- $\beta$  treatment is remarkably fast. Activation of CXCR2 signaling in endothelial cells has been reported to lead to endothelial cell contraction (64, 65) and weakening of intercellular junctions (66, 67). In accordance with these reports, we detected increased permeability of vascular cells after CXCR2 stimulation in vivo and in vitro (Zhang, J and Link, DC, unpublished observations). Increased vascular leakiness has also been found in the BM of tGro- $\beta$  treated mice (52) and is likely a major contributor to the brisk kinetics of tGro- $\beta$  triggered HSPC emigration (Figure 6C). Moreover, though not addressed in our analysis directly, an involvement of the complement cascade, a key orchestrator of pharmacologically and pathologically induced HSPC release from the BM (68, 69), and the associated release of anaphylatoxins might have facilitated increased vascular permeability. The latter are further known to stimulate the release of the lipolytic enzyme phospholipase C  $\beta$ 2 (PLCB2), which in turn disrupts lipid raft formation needed for optimal signaling via VLA4 and CXCR4 (68, 70).

Adhesive interactions and cross-stimulation between CXCR2 expressing granulocytes and endothelia are critical for the increased permeability and likely also for the subsequent cell-cell contact or soluble mediator-enabled HSPC release in the context of mobilization with tGro- $\beta$  alone. However, in contrast to the reported requirement of LFA1 for IL-8 induced mobilization (19), neither deficiency for LFA1 nor for Mac1 enhanced tGro- $\beta$  mediated HSPC egress. Loss of one beta 2 integrin was possibly compensated by the presence of the other along with other integrins. With regard to the HSPC population targeted, similarly to VLA4 antagonist alone, the transplant data suggested predominant mobilization of progenitor cells with tGro- $\beta$ . Hence, elevated vascular permeability and reduced retention induced by tGro- $\beta$  alone are not sufficient to release the HSCs from their protective BM environment.

Finally, when tGro- $\beta$  is combined with a second stimulus in the form of VLA4 inhibition, in addition to the reciprocal stimulation of CXCR2 expressing cells, the associated changes in permeability as well as cell contact and / or soluble mediator induced decreased HSPC retention, the latter is further hit by lack of VLA4 signaling (Figure 6D). As demonstrated by the results of the serial competitive transplantation analysis, this combination of events indeed recruited with high efficiency highly engraftable, true HSCs into the circulation. Cross-stimulation of tGro- $\beta$  targeted cells being dependent on integrin interactions, blockade of both, VLA4 and either LFA1 or Mac1, appears to disturb rolling and adhesion and therefore proximity of CXCR2 expressing cells to an extent that cannot be compensated, unlike when tGro- $\beta$  is given alone. This concept could explain the relatively less efficient mobilization with VLA4 antagonist plus tGro- $\beta$  in mice lacking beta 2 integrins.

In summary, we show that simultaneous administration of CXCR2 agonists in conjunction with VLA4 small molecule inhibitors results in rapid and robust mobilization of HPCs and HSCs. A contribution of hematopoietic (neutrophils) and non-hematopoietic (endothelial) CXCR2 to the mobilization response was found. Grafts mobilized with the VLA4 inhibitor + tGro- $\beta$  combination exhibited serial repopulating capacity. Given several advantages of this combination over currently approved HSPC mobilization methods, it represents an exciting potential strategy for clinical development in the future. We are continuing to optimize the pharmacokinetic and pharmacodynamic properties of the VLA4 inhibitors to enable future large animal efficacy and toxicology studies in non-human primates which will be currently underway. Further, our data support the proposed perisinusoidal localization of very primitive (true) HSCs and will also serve as a tool to learn more about the interplay between mature hematopoietic cells, non-hematopoietic stroma and stem cells.

## Methods

### Mice

Male 6-12 week old wild-type BALB/cJ (CD45.2), BALB/cByJ (CD45.2) and syngeneic CByJ.SJL(B6)-Ptprca/J (CD45.1) as well as wild-type C57BL/6J and syngeneic B6.SJL-Ptprca<sup>a</sup> Pep3<sup>b</sup>/BoyJ (CD45.1), wild-type DBA/2J and FVB/NJ mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The knockout strains C.129S2(B6)-Cxcr2tm1Mwm/J (CXCR2 KO, BALB/cJ background), B6.FVB(Cg)-Mmp9tm1Tvu/J (MMP9 ko, C57BL/6J background), FVB.Cg-Mmp9tm1Tvu/J (MMP9 KO, FVB/NJ background), B6.129S7-Itgal<sup>tm1Bl</sup>/J (CD11a KO, C57BL/6J background) and B6.129S4-Itgam<sup>tm1Myd</sup>/J (CD11b KO, C57BL/6J background) were also obtained from Jackson Laboratory. Endothelial specific CXCR2 ablated mice were generated by crossing C57BL/6-Cxcr2tm1Rmra/J (CXCR2<sup>fl/fl</sup>, Jackson Laboratory) and B6;129-Tg(Cdh5-cre)1Spe/J (Cdh5Cre, Jackson Laboratory) mice. Mobilization experiments were performed with Cxcr2<sup>fl/fl</sup>Cre<sup>+</sup> mice (CXCR2<sup>fl/WT</sup>Cre<sup>+</sup> were used as controls) reconstituted with wild-type BM from syngeneic B6.SJL-Ptprca<sup>a</sup> Pep3<sup>b</sup>/BoyJ (CD45.1, Jackson Laboratory) donors. Following lethal irradiation (1x 9.5 -11 Gy, using a Caesium source) and transplantation, mice were kept on antibiotic medication, sulfamethoxazole and trimethoprim, 0.5 and 0.1 mg/ml respectively, (HI-Tech Pharmacal, Amityville, NY, USA) p. o. in drinking water.

### Cell and tissue preparation

Peripheral blood (PB) and bone marrow (BM) cells were recovered as described previously (12). Cell counts (WBC) were measured on an automatic hemocytometer (Hemavet 950, Drew Scientific, Dallas, TX). Total counts (per tissue) as well as the majority of functional analysis were performed with filtered and otherwise unmanipulated cell suspensions, whereas red cells were removed from suspensions prepared for flow cytometry using hypotonic lysis. Absolute numbers of immunophenotypically defined populations (e.g. LSK) were calculated assuming CD45 positive cells are equivalent to WBC from the corresponding cell count analysis.

### **In vivo reagents and treatments**

Human recombinant truncated Gro- $\beta$  peptide (tGro- $\beta$ , CXCL2, SB-251353 from GlaxoSmithKline, Brentford, UK) was used for all in vivo experiments. Stock solution(52) stored at -80 °C) was freshly thawed and diluted immediately prior to the s.c. injection (2.5 mg/kg). Murine recombinant CXCL1 (PeproTech, Inc., Rocky Hill, NJ) and human recombinant CXCL8 (aa 23-99, Sino Biological, Wayne, PA) stock solutions were prepared in water. All chemokines were diluted in PBS (GE Healthcare Life Sciences, Logan, UT, USA) or directly in the CWHM-823 solution. CWHM-823+chemokine mixtures were sonicated in a water bath for 15-30 min prior to injection to counteract precipitation. Firategrast was synthesized based on the published structure (C<sub>27</sub>H<sub>27</sub>F<sub>2</sub>NO<sub>6</sub>; patent #US2014051655), dissolved in a 1% Ethanol solution in PBS and injected i.v. or s.c. (100 mg/kg). Mice treated with Firategrast+tGro- $\beta$  received two separate injections. All other VLA4 antagonists, BIO5192(28) (TOCRIS, Bio-Techne Corporation, Minneapolis, MN), CWHM-842, 822, 823, 824 and 825 were dissolved in DMSO (100x stock solution) and diluted in NaHCO<sub>3</sub>:NaCl buffer (1:1, 10 mM NaHCO<sub>3</sub>, pH 8 : 0.9% w/v NaCl) for subsequent i.v., s.c. (CWHM-823 only) or i.p (CWHM-823 only) injection at 3 mg/kg. BIO5192+tGro- $\beta$  and CWHM-842+tGro- $\beta$  treatment consisted of two separate injections, whereas CWHM-823+Gro- $\beta$  was administered either as two injections (VLA4 antagonist i.v., tGro- $\beta$  s.c.) or as one injection (i.v., i.p. or s.c.) as specified for each experiment. AMD3100 (Mozobil<sup>®</sup>, Genzyme, Cambridge, MA, USA) suspension was prepared in PBS and administered s.c (5 mg/kg). AMD3100+ tGro- $\beta$  mixture was prepared by diluting tGro- $\beta$  into the AMD3100 solution and also injected s.c.. RhG-CSF (Neupogen<sup>®</sup>, Filgrastim, Amgen, Thousand Oaks, CA, USA) diluted in PBS was injected i.p. every 12 hrs at a dose of 100  $\mu$ g/kg for a total of 4 (day 3) or 9 (day 5) doses. Broad spectrum matrix metalloprotease inhibitor Batimastat (BB-94, APExBio, Houston, Tx)) was dissolved in DMSO, diluted in corn oil (Sigma-Aldrich, St. Louis, MO), vortexed thoroughly and injected i.p. 12 and 2 hrs (25 mg/kg) prior to the mobilization treatment. Control mice received DMSO/corn oil injections. In all other experiments, mice injected with PBS, PBS/DMSO or left untreated (baseline) at the timepoint of analysis will be referred to as control (ctr) animals throughout the manuscript.

### **Depletion of granulocytes**

To deplete granulocytes in vivo the anti-mouse Ly6G/Ly6C antibody (Gr1, Clone RB6-8C5, BioXCell Inc, West Lebanon, NH) was administered i.v. (200 µg/mouse) 36 hrs prior to the mobilization treatment. Control mice were treated with an isotype control antibody (clone 2A3, BioXCell). Efficient depletion of peripheral blood granulocytes was confirmed using differential blood count as well as flow cytometric analysis.

### **Induction of Diabetes**

Diabetes was induced in 8-week-old BALB/cj mice by a single i.p. injection of 200 mg/kg Streptozotocin (SZT, EMD Millipore, Billerica, MA) dissolved in citrate buffer (pH 4.7-5.3, Sigma-Aldrich). Blood glucose levels were measured with a portable blood glucose meter (Glucocard Vital, ARKRAY USA Inc., Minneapolis, MN, USA). Animals with glucose values higher than 300 mg/dl were used for mobilization experiments 2-3 weeks post SZT injection.

### **Transplantation**

*Serial Competitive Transplantation:* Lethally irradiated CD45.2 BALB/cj hosts received i.v. transplants consisting of  $2.5 \times 10^5$  CD45.2 BM cells and a small volume (10 µl) of differentially mobilized blood (BALB/cj CD45.1): G-CSF (5 days) vs. tGro-β vs. VLA4 antagonist Firategrast or CWHM-823 vs. VLA4 antagonist+tGro-β). 20 weeks after the transplantation PB composition of the recipients was analyzed for the presence of blood graft-derived hematopoiesis i.e. percent contribution of blood donor CD45.1+ cells within the CD45+CD3- compartment. Following PB analysis BM cells of the primary recipients were isolated and pooled based on WBC counts at equal proportion per recipient per group (G-CSF and both VLA4 antagonist + tGro-β groups).  $2.5 \times 10^6$  of the primary recipient BM cell mixture were injected per mouse into lethally irradiated secondary recipients (CD45.2). PB analysis of

secondary hosts was performed 18 weeks after the transplantation. Similarly, CD45.1+ percentage within the CD45+CD3- fraction was determined.

*Generation of transplantation chimeras for mobilization:* To generate hematopoietic specific CXCR2 knockout mice,  $1 \times 10^6$  BM cells from CXCR2 knockout animals (CD45.2) were transplanted into lethally irradiated wildtype syngeneic BALB/cj CD45.1+ recipients. Control group of 45.1+ hosts received wildtype CD45.2 BM cells. Conversely, stromal specific knockouts were generated by transplanting lethally irradiated CXCR2 knockout animals with  $1 \times 10^6$  CD45.1 wildtype BM cells. In the corresponding control group wildtype CD45.2 hosts received 45.1 BM grafts.

For endothelial cell specific CXCR2 ablation, lethally irradiated CXCR2<sup>fl/fl</sup>Cdh5Cre+ hosts (C57BL/6 background, CD45.2) were reconstituted with syngeneic wildtype CD45.1+ BM ( $3 \times 10^6$  cells per recipient). In the control group CXCR2<sup>fl/wt</sup>Cre+ and CXCR2<sup>wt/wt</sup>Cre+ mice were used as recipients. Mobilization studies in chimeric animals were started 8-12 weeks after the transplant. Lack of contribution of recipient endogenous hematopoiesis was verified by flow cytometry in each recipient.

### **Fluorescence activated cell analysis and sorting (FACS)**

Cell labeling was performed according to standard protocols using established marker panels for identification of different subsets in mouse hematopoietic tissues as described previously (10, 12). Lineage negative and c-Kit positive (Lin- kit+) or Lineage negative, Sca-1 positive and c-Kit positive cells (LSK) were an estimate for HSPCs, whereas HSCs were identified as LSK SLAM (LSK CD150+ CD48-) cells. Antibodies used in this study are listed in Suppl. Table 6. Sample acquisition was performed on a Gallios™ (Beckman Coulter Life Sciences, Indianapolis, IN, USA) and BD LSRFortessa™ (BD Biosciences, San Jose, CA, USA) flow cytometer or BD FACS Aria II cell sorter (BD Biosciences). Data were further analyzed using FlowJo software (Tree Star, Inc., Ashland, OR, USA) or FACSDiva software (BD Biosciences). Cell isolation by flow sorting was performed on BD FACS Aria II. Cell cycle analysis was performed as described previously (10, 12).

### **Colony forming unit assay**

Cells were incubated in duplicate in commercially available growth factor supplemented methylcellulose medium for mouse CFU-C (Stem Cell Technologies, Vancouver, BC or R&D Systems, Minneapolis, MN, USA) as described(10, 12). CFU-C (BFU-E, CFU-GM and CFU-GEMM) were enumerated after 6-8 days of culture.

### **Quantitative Real-Time PCR**

For analysis of gene expression in cell populations (LSK, LSK SLAM and different mature cell fractions) sorted from the BM RNA was isolated using RNA XS column kit (Machery-Nagel, Bethlehem, PA, USA). Ambion Turbo DNA-free™ Kit (Thermo Fisher Scientific) was then used to remove genomic DNA followed by reverse transcription of the RNA using the QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA, USA). qRT-PCR (*Cxcr2* and *Gapdh*) was performed using TaqMan Master Mix, probes and primers (Applied Biosystems, Foster City, CA, USA) listed in Suppl. Table 7.

### **Microarray Analysis**

RNA from LSK cells sorted from untreated BM or PB of differentially mobilized (G-CSF (5 days), AMD3100 or CWHM-823 + Gro- $\beta$ , single injection) mice was prepared using the RNA XS column kit (Machery-Nagel) and hybridized to the Mouse Gene Expression v2 4x44K microarray (Agilent Technologies, Santa Clara, CA, USA). Normalization and quality assessment of expression data was performed using Partek Genomic Suite® (Partek Inc., Chesterfield, MO, USA). Thus, log<sub>2</sub> scale transformed and filtered expression data were used for PCA plot generation. Hierarchical clustering was performed using top 1000 differentially (significance) regulated genes. Expression data can be accessed at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123505>.

### **Pharmacokinetics**

Peripheral blood (PB) was drawn from the facial vein without anaesthesia and collected into lithium heparin anti-coagulated tubes (Sarstedt AG & Co, Nümbrecht, Germany). If not processed immediately samples were stored on ice ( $\leq 1$  hr). After centrifugation (25 min, 3000-4000 rpm, 4 °C) plasma supernatant was carefully removed, frozen and stored at  $<-80$  °C until just before analysis. Plasma samples or standards prepared in plasma matrix (50  $\mu$ L) were added to a 96-well plate. To each well, 200  $\mu$ L of cold acetonitrile containing 100 ng/mL extraction internal standard enalapril was added. The plate was vortexed for 5 minutes, and then centrifuged at 3200 rpm for 5 minutes at 4°C. The supernatant (200  $\mu$ L) was transferred to a second 96-well plate, evaporated to dryness under nitrogen, reconstituted with 100  $\mu$ L of 0.1% v/v formic acid in 9:1 water:acetonitrile, vortexed for 5 minutes, and the samples were analyzed by LC/MS. CWHM-823 concentrations were determined on a Sciex API-4000 LC/MS system (SCIEX, Framingham, CA, USA), in positive electrospray mode. Analytes were eluted from an Armor C18 reverse phase column (2.1 x 30 mm, 5  $\mu$ m) using a 0.1% formic acid mobile phase system with aqueous to acetonitrile gradient over 3.7 minutes at a flow rate of 0.35 mL/min. Peak areas for the mass transition of  $m/z$  518 > 472 for CWHM-823 and  $m/z$  376 > 91 for enalapril (IS) were integrated using Analyst 1.5.1 software. Peak area ratios of CWHM-823 area/enalapril area were plotted against standard concentrations with a  $1/x$ -weighted linear regression.

### **Water Solubility Assay**

For each VLA4 antagonist tested, 1-2 mg of solid compound were placed in an Eppendorf tube with 1 mL of equilibrium solubility buffer (ESB, 50 mM citric acid, 50 mM  $K_2HPO_4$ , 50 mM Ammediol and 50 mM KCl, pH 7) and incubated in a Thermomixer for 48 hours at 25 °C at 500 rpm. After 24 hours, tubes were centrifuged at 3000 xg for 5 minutes, and an aliquot of the supernatant was removed and diluted into linear standard range of the standard curve for the LCMS method. Sample dilutions and standards were made in 75:25 ESB:acetonitrile. Firategrast, BIO5192, CWHM-823, CWHM-824, CWHM-825, and CWHM-842 concentrations were determined on a Sciex API-4000 LC/MS system (SCIEX) in positive electrospray mode. Analytes were eluted from an Armor C18 reverse phase column (2.1 x 30 mm, 5

µm) using a 0.1% formic acid mobile phase system with aqueous to acetonitrile gradient over 3.7 minutes at a flow rate of 0.35 mL/min. Peak areas for the mass transition of m/z 500.3 > 454.2 for fimategrast, m/z 817.2 > 394.0 for BIO5192, m/z 505.0 > 176.0 for CWHM 822, m/z 518.0 > 472.2 for CWHM-823, m/z 621.2 > 575.0 for CWHM-824, m/z 474.6 > 192.2 for CWHM-825, and m/z 523.4 > 390.2 for CWHM-842 were integrated using Analyst 1.5.1 software (SCIEX). Peak areas were plotted against standard concentrations with a 1/x-weighted linear regression.

### **VCAM1 binding assay**

G2 ALL cells ( $1.5 \times 10^5$  cells per sample, The Hospital for Sick Children, Toronto, ON, Canada) were incubated with increasing concentrations of the different VLA4 antagonists for 30 minutes at room temperature (RT). Subsequently, human recombinant VCAM1/Fc chimera protein (R&D Systems) was added to the samples at a final concentration of 10 µg/mL. After a second 30 min incubation step at RT, cells were washed twice with HBSS/0.1% BSA buffer and secondary antibody (PE-labeled donkey anti-human IgG, catalog number 709-116-098, Jackson ImmunoResearch Laboratories, West Grove, PA) added at 1:100 dilution. Control samples were stained with PE-labeled donkey IgG (catalog number 017-110-006, Jackson ImmunoResearch Laboratories, 1:100 dilution). Secondary antibody staining was performed at RT for 30 min. Following addition of 7-AAD for 5 min at RT, cells were washed twice with HBSS/BSA buffer and analyzed by flow cytometry.

### **Integrin Binding Assay**

The potency of compounds in blocking ligand binding to integrins  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  was determined by modification of our previously described methods(71). Briefly, purified human VCAM1 (R&D Systems) diluted to 5 µg/ml in TBS+ buffer (25 mM Tris pH 7.4, 137 mM NaCl, 2.7 mM KCl, 1mM  $\text{CaCl}_2$ , 1 mM  $\text{MgCl}_2$ , 1 mM  $\text{MnCl}_2$ ) was added to wells of a 96-well transparent microtiter plate and incubated overnight at 4°C. Wells were washed 3 times with TBS+ and blocking buffer (TBS+ with 1% bovine serum albumin), the plate was incubated for 1 hr at 37°C, and then washed 3× with TBS+

buffer. Recombinant human integrin ITGA4/ITGB1 ( $\alpha 4\beta 1$ ; VLA4) or ITGA4/ITGB7 ( $\alpha 4\beta 7$ ) (R&D Systems) was diluted to 1  $\mu\text{g}/\text{ml}$  in TBS+/0.1% bovine serum albumin. Test compounds were diluted into the integrin solution and added to the washed ligand-coated plate according to a standard template with each sample repeated in triplicate. After incubation for 2 hr at room temperature, the plate was washed 3 $\times$  with 150  $\mu\text{l}$  of TBS+ buffer. To each well, biotinylated anti- $\beta 1$  (catalog number BAF1778, R&D Systems) or anti-  $\alpha 4$  antibody (Clone 7.2R, R&D Systems) at 1  $\mu\text{g}/\text{ml}$  in TBS+/0.1%BSA was added and the plate covered and incubated for 1 hr at room temperature. After washing the plate 3 $\times$  with TBS+ buffer, streptavidin-conjugated horseradish peroxidase (R&D Systems) diluted in TBS+ blocking buffer was added to the wells and the plate incubated for 20 min at room temperature. The plate was washed 3 $\times$  with TBS+ buffer followed by addition of 50  $\mu\text{l}$  of TMB substrate (Sigma). After incubation for 20 min at room temperature, plates were read by colorimetric detection at 650 nm wavelength using a Tecan Safire II plate reader. Concentration-response curves were constructed by non-linear regression (best fit) analysis, and  $\text{IC}_{50}$  values were calculated for each compound.

To evaluate the broader selectivity of test compounds, potency against a non-targeted beta-1-subunit-containing integrin, ITGA2/ITGB1 ( $\alpha 2\beta 1$ ), was measured as described previously (71). Assessment of compound potency against two selected members of the RGD-binding integrin family, ITGA5/ITGB1 ( $\alpha 5\beta 1$ ) and ITGAV/ITGB3 ( $\alpha v\beta 3$ ), was determined by a similar method in which binding of the purified human integrins (R&D Systems) was assessed to plates coated with their respective purified ligands, human fibronectin (2  $\mu\text{g}/\text{ml}$ , R&D Systems) and human vitronectin (1  $\mu\text{g}/\text{ml}$ ; R&D Systems). Biotinylated anti-ITGAV ( $\alpha v$ ) or anti-ITGA5 ( $\alpha 5$ ; R&D Systems) antibodies were used to detect the stably bound integrins in conjunction with streptavidin-conjugated horseradish peroxidase as described above. The  $\alpha v\beta 3$  and  $\alpha 5\beta 1$  assays were validated by inclusion of a known potent inhibitor of these integrins, CWHM-12 (71), while the  $\alpha 2\beta 1$  assay was validated by inclusion of another previously described inhibitor, Compound 8 (72) (data not shown).

### **Specificity Screening**

tGro- $\beta$  was sent out to DiscoverX (DiscoverX Corporation, Fremont, CA, USA) for blinded profiling against the gpcrMAX Panel (148 G-Protein coupled receptors screened in both, agonist and antagonist mode) using the PathHunter beta-arrestin enzyme fragmentation (EFC) technology.

### **Statistics**

Data are shown as mean  $\pm$  SEM unless indicated otherwise. Linear mixed models were used to analyse experiments with data repeatedly measured from the same mice, while analysis of variance (ANOVA) were used for data from independent samples. A logarithm transformation was performed as necessary to better satisfy the normality and homoscedasticity assumptions (see Figure legends for details). Ad-hoc multiple comparisons were also used for between-group differences of interest. The resultant p-values were adjusted by Holm's step-down Bonferroni adjustment. Compared to the widely used Bonferroni adjustment, a step-down method is more powerful (smaller adjusted p-values) while maintaining strong control of the familywise error rate. All analyses were two-sided and significance was set at a p-value of 0.05. The statistical analyses were performed using SAS 9.4 (SAS Institutes, Cary, NC).

### **Study approval**

All animals were housed at the Washington University Medical School vivarium under SPF conditions with autoclaved chow and water ad libitum. All experiments were performed in accordance with the guidelines of the Washington University Animal Studies Committee, approved by the institutional animal care and use committee (IACUC), in agreement with AAALAC guidelines.

**Author contributions**

DK, MPR and JFD conceived of the study. DK, MPR, JR, SC, LG, EC, DC, MOE, MH, JZ, GA, HC, EW, WY, LGE, RFH, SDA, MJM, MJP, DWG, PGR, DMM performed experiments. DK, MPR and DC analysed data. WY assisted with microarray data processing and analysis. FG assisted with the statistical analysis of the data. DK, MPR, AT, HBB, DCL and JFD supervised research. DK wrote the manuscript. All authors discussed, commented on and approved the final version of the manuscript.

## **Acknowledgements**

DK is a past scholar of the German Academic Exchange Service (Postdoctoral fellowship-ID: 57054578, 2014-2016). M.P.R. is supported by the National Institutes of Health, National Cancer Institute (R50 CA211466) and an Alvin J. Siteman Cancer Center, Siteman Investment Program award that is supported by The Foundation for Barnes-Jewish Hospital Cancer Frontier Fund, Barnard Trust, and National Cancer Institute Cancer Center Support Grant (P30 CA091842). H.C. was supported by the American Society of Hematology and the Edward P. Evans Foundation. HB is a member of LOEWE Cell and Gene Therapy Frankfurt faculty, funded by Hessian Ministry of Higher Education, Research and the Arts ref.no.: III L 4- 518/17.004 (2010-2018). J.F.D. is supported by grants from the National Institutes of Health, National Cancer Institute (U54 CA199092, R01 CA152329 and R35 CA210084). We thank the Genome Technology Access Center in the Department of Genetics at Washington University School of Medicine for help with genomic analysis. The Center is partially supported by NCI Cancer Center Support Grant #P30 CA91842 to the Siteman Cancer Center and by ICTS/CTSA Grant # UL1RR024992 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. This publication is solely the responsibility of the authors and does not necessarily represent the official view of NCRR or NIH. We thank the Alvin J. Siteman Cancer Center at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis, Mo., for the use of the Siteman Flow Cytometry Core. The Siteman Cancer Center is supported in part by an NCI Cancer Center Support Grant #P30 CA91842

## References

1. Gao X, Xu C, Asada N, and Frenette PS. The hematopoietic stem cell niche: from embryo to adult. *Development*. 2018;145(2).
2. Frisch BJ. The hematopoietic stem cell niche: What's so special about bone? *Bone*. 2018.
3. Molineux G, Pojda Z, Hampson IN, Lord BI, and Dexter TM. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. *Blood*. 1990;76(10):2153-8.
4. Bonig H, and Papayannopoulou T. Hematopoietic stem cell mobilization: updated conceptual renditions. *Leukemia*. 2013;27(1):24-31.
5. Domingues MJ, Nilsson SK, and Cao B. New agents in HSC mobilization. *Int J Hematol*. 2017;105(2):141-52.
6. Christopher MJ, Liu F, Hilton MJ, Long F, and Link DC. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. *Blood*. 2009;114(7):1331-9.
7. Rettig MP, Ansstas G, and DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. *Leukemia*. 2012;26(1):34-53.
8. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *The Journal of experimental medicine*. 2005;201(8):1307-18.
9. Bonig H, Chudziak D, Priestley G, and Papayannopoulou T. Insights into the biology of mobilized hematopoietic stem/progenitor cells through innovative treatment schedules of the CXCR4 antagonist AMD3100. *Experimental hematology*. 2009;37(3):402-15 e1.
10. Karpova D, Dauber K, Spohn G, Chudziak D, Wiercinska E, Schulz M, et al. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor. *Leukemia*. 2013;27(12):2322-31.
11. Karpova D, and Bonig H. Concise Review: CXCR4/CXCL12 Signaling in Immature Hematopoiesis--Lessons From Pharmacological and Genetic Models. *Stem cells*. 2015;33(8):2391-9.
12. Karpova D, Ritchey JK, Holt MS, Abou-Ezzi G, Monlish D, Batoon L, et al. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells. *Blood*. 2017;129(21):2939-49.
13. Abraham M, Biyder K, Begin M, Wald H, Weiss ID, Galun E, et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. *Stem cells*. 2007;25(9):2158-66.
14. Bonig H, Wundes A, Chang KH, Lucas S, and Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. *Blood*. 2008;111(7):3439-41.
15. Moepps B. *Compendium of Inflammatory Diseases*. 2016:394-404.
16. Laterveer L, Lindley IJ, Hamilton MS, Willemze R, and Fibbe WE. Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. *Blood*. 1995;85(8):2269-75.


17. Pelus LM, and Fukuda S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. *Experimental hematology*. 2006;34(8):1010-20.
18. Fibbe WE, Pruijt JF, Velders GA, Opdenakker G, van Kooyk Y, Figdor CG, et al. Biology of IL-8-induced stem cell mobilization. *Ann N Y Acad Sci*. 1999;872:71-82.
19. Pruijt JF, van Kooyk Y, Figdor CG, Lindley IJ, Willemze R, and Fibbe WE. Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. *Blood*. 1998;91(11):4099-105.
20. Hipkin RW, Deno G, Fine J, Sun Y, Wilburn B, Fan X, et al. Cloning and pharmacological characterization of CXCR1 and CXCR2 from *Macaca fascicularis*. *J Pharmacol Exp Ther*. 2004;310(1):291-300.
21. Karpova D, Brauninger S, Wiercinska E, Kramer A, Stock B, Graff J, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. *J Transl Med*. 2017;15(1):2.
22. Schroeder MA, Rettig MP, Lopez S, Christ S, Fiala M, Eades W, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. *Blood*. 2017;129(19):2680-92.
23. Wei Q, and Frenette PS. Niches for Hematopoietic Stem Cells and Their Progeny. *Immunity*. 2018;48(4):632-48.
24. Miller DH, Weber T, Grove R, Wardell C, Horrigan J, Graff O, et al. Finategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. *The Lancet Neurology*. 2012;11(2):131-9.
25. Kim AG, Vrecenak JD, Boelig MM, Eissenberg L, Rettig MP, Riley JS, et al. Enhanced in utero allogeneic engraftment in mice after mobilizing fetal HSCs by alpha4beta1/7 inhibition. *Blood*. 2016;128(20):2457-61.
26. King AG, Horowitz D, Dillon SB, Levin R, Farese AM, MacVittie TJ, et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. *Blood*. 2001;97(6):1534-42.
27. Fukuda S, Bian H, King AG, and Pelus LM. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. *Blood*. 2007;110(3):860-9.
28. Ramirez P, Rettig MP, Uy GL, Deych E, Holt MS, Ritchey JK, et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. *Blood*. 2009;114(7):1340-3.
29. Duplantier AJ, Beckius GE, Chambers RJ, Chupak LS, Jenkinson TH, Klein AS, et al. Isoxazolyl, oxazolyl, and thiazolylpropionic acid derivatives as potent alpha(4)beta(1) integrin antagonists. *Bioorg Med Chem Lett*. 2001;11(19):2593-6.
30. Hagmann WK, Durette PL, Lanza T, Kevin NJ, de Laszlo SE, Kopka IE, et al. The discovery of sulfonlated dipeptides as potent VLA-4 antagonists. *Bioorg Med Chem Lett*. 2001;11(20):2709-13.
31. Kamenecka TM, Lanza T, Jr., de Laszlo SE, Li B, McCauley ED, Van Riper G, et al. N-aryl-propyl-dipeptides as potent antagonists of VLA-4. *Bioorg Med Chem Lett*. 2002;12(16):2205-8.
32. Kudlacz E, Whitney C, Andresen C, Duplantier A, Beckius G, Chupak L, et al. Pulmonary eosinophilia in a murine model of allergic inflammation is attenuated by small molecule alpha4beta1 antagonists. *J Pharmacol Exp Ther*. 2002;301(2):747-52.

33. Li B, de Laszlo SE, Kamenecka TM, Kopka IE, Durette PL, Lanza T, Jr., et al. N-(arylacetyl)-biphenylalanines as potent VLA-4 antagonists. *Bioorg Med Chem Lett*. 2002;12(16):2141-4.
34. Sircar I, Gudmundsson KS, Martin R, Liang J, Nomura S, Jayakumar H, et al. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual  $\alpha(4)\beta(7)/\alpha(4)\beta(1)$  integrin antagonist. *Bioorg Med Chem*. 2002;10(6):2051-66.
35. DiPersio JF. Diabetic stem-cell "mobilopathy". *N Engl J Med*. 2011;365(26):2536-8.
36. Ferraro F, Lymperi S, Mendez-Ferrer S, Saez B, Spencer JA, Yeap BY, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. *Sci Transl Med*. 2011;3(104):104ra1.
37. Land RH, Rayne AK, Vanderbeck AN, Barlowe TS, Manjunath S, Gross M, et al. The orphan nuclear receptor NR4A1 specifies a distinct subpopulation of quiescent myeloid-biased long-term HSCs. *Stem cells*. 2015;33(1):278-88.
38. Reutershan J, Morris MA, Burcin TL, Smith DF, Chang D, Saprito MS, et al. Critical role of endothelial CXCR2 in LPS-induced neutrophil migration into the lung. *The Journal of clinical investigation*. 2006;116(3):695-702.
39. Hale SJ, Hale AB, Zhang Y, Sweeney D, Fisher N, van der Garde M, et al. CXCR2 modulates bone marrow vascular repair and haematopoietic recovery post-transplant. *British journal of haematology*. 2015;169(4):552-64.
40. Zhang J, and Link DC. Targeting of Mesenchymal Stromal Cells by Cre-Recombinase Transgenes Commonly Used to Target Osteoblast Lineage Cells. *J Bone Miner Res*. 2016;31(11):2001-7.
41. Greenbaum A, Hsu YM, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN, et al. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance. *Nature*. 2013;495(7440):227-30.
42. Lefort CT, and Ley K. Neutrophil arrest by LFA-1 activation. *Front Immunol*. 2012;3:157.
43. Weber C, and Springer TA. Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to  $\alpha\text{IIb}\beta(3)$  and stimulated by platelet-activating factor. *The Journal of clinical investigation*. 1997;100(8):2085-93.
44. Seo SM, McIntire LV, and Smith CW. Effects of IL-8, Gro- $\alpha$ , and LTB(4) on the adhesive kinetics of LFA-1 and Mac-1 on human neutrophils. *Am J Physiol Cell Physiol*. 2001;281(5):C1568-78.
45. Gronholm M, Jahan F, Bryushkova EA, Madhavan S, Aglialaro F, Soto Hinojosa L, et al. LFA-1 integrin antibodies inhibit leukocyte  $\alpha(4)\beta(1)$ -mediated adhesion by intracellular signaling. *Blood*. 2016;128(9):1270-81.
46. Magazin M, Vita N, Cavrois E, Lefort S, Guillemot JC, and Ferrara P. The biological activities of gro  $\beta$  and IL-8 on human neutrophils are overlapping but not identical. *Eur Cytokine Netw*. 1992;3(5):461-7.
47. Velders GA, Pruijt JF, Verzaal P, van Os R, van Kooyk Y, Figdor CG, et al. Enhancement of G-CSF-induced stem cell mobilization by antibodies against the  $\beta(2)$  integrins LFA-1 and Mac-1. *Blood*. 2002;100(1):327-33.
48. Hidalgo A, Peired AJ, Weiss LA, Katayama Y, and Frenette PS. The integrin  $\alpha(4)\beta(1)$  anchors hematopoietic progenitors in the bone marrow during enforced mobilization. *Blood*. 2004;104(4):993-1001.


49. Fibbe WE, Pruijt JF, van Kooyk Y, Figdor CG, Opdenakker G, and Willemze R. The role of metalloproteinases and adhesion molecules in interleukin-8-induced stem-cell mobilization. *Semin Hematol.* 2000;37(1 Suppl 2):19-24.
50. Pruijt JF, Fibbe WE, Laterveer L, Pieters RA, Lindley IJ, Paemen L, et al. Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). *Proc Natl Acad Sci U S A.* 1999;96(19):10863-8.
51. Pelus LM, Bian H, King AG, and Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. *Blood.* 2004;103(1):110-9.
52. Hoggatt J, Singh P, Tate TA, Chou BK, Datari SR, Fukuda S, et al. Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell. *Cell.* 2018;172(1-2):191-204 e10.
53. Morrison SJ, Wright DE, and Weissman IL. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. *Proc Natl Acad Sci U S A.* 1997;94(5):1908-13.
54. Winkler IG, Wiercinska E, Barbier V, Nowlan B, Bonig H, and Levesque JP. Mobilization of hematopoietic stem cells with highest self-renewal by G-CSF precedes clonogenic cell mobilization peak. *Experimental hematology.* 2016;44(4):303-14 e1.
55. Liu F, Poursine-Laurent J, and Link DC. Expression of the G-CSF receptor on hematopoietic progenitor cells is not required for their mobilization by G-CSF. *Blood.* 2000;95(10):3025-31.
56. Levesque JP, Helwani FM, and Winkler IG. The endosteal 'osteoblastic' niche and its role in hematopoietic stem cell homing and mobilization. *Leukemia.* 2010;24(12):1979-92.
57. Grassinger J, Williams B, Olsen GH, Haylock DN, and Nilsson SK. Granulocyte colony stimulating factor expands hematopoietic stem cells within the central but not endosteal bone marrow region. *Cytokine.* 2012;58(2):218-25.
58. Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, Larocca R, et al. In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. *Nature.* 2011;474(7350):216-9.
59. Bowers E, Slaughter A, Frenette PS, Kuick R, Pello OM, and Lucas D. Granulocyte-derived TNFalpha promotes vascular and hematopoietic regeneration in the bone marrow. *Nature medicine.* 2018;24(1):95-102.
60. Pruijt JF, Verzaal P, van Os R, de Kruijf EJ, van Schie ML, Mantovani A, et al. Neutrophils are indispensable for hematopoietic stem cell mobilization induced by interleukin-8 in mice. *Proc Natl Acad Sci U S A.* 2002;99(9):6228-33.
61. Blaser BW, Moore JL, Hagedorn EJ, Li B, Riquelme R, Lichtig A, et al. CXCR1 remodels the vascular niche to promote hematopoietic stem and progenitor cell engraftment. *The Journal of experimental medicine.* 2017;214(4):1011-27.
62. Pruijt JF, van Kooyk Y, Figdor CG, Willemze R, and Fibbe WE. Murine hematopoietic progenitor cells with colony-forming or radioprotective capacity lack expression of the beta 2-integrin LFA-1. *Blood.* 1999;93(1):107-12.
63. Papayannopoulou T. Mechanisms of stem-/progenitor-cell mobilization: the anti-VLA-4 paradigm. *Semin Hematol.* 2000;37(1 Suppl 2):11-8.

64. Schraufstatter IU, Chung J, and Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. *Am J Physiol Lung Cell Mol Physiol.* 2001;280(6):L1094-103.
65. Lei X, Hossain M, Qadri SM, and Liu L. Different microvascular permeability responses elicited by the CXC chemokines MIP-2 and KC during leukocyte recruitment: role of LSP1. *Biochem Biophys Res Commun.* 2012;423(3):484-9.
66. Gavard J, Hou X, Qu Y, Masedunskas A, Martin D, Weigert R, et al. A role for a CXCR2/phosphatidylinositol 3-kinase gamma signaling axis in acute and chronic vascular permeability. *Mol Cell Biol.* 2009;29(9):2469-80.
67. Dwyer J, Hebda JK, Le Guelte A, Galan-Moya EM, Smith SS, Azzi S, et al. Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2. *PloS one.* 2012;7(9):e45562.
68. Borkowska S, Suszynska M, Mierzejewska K, Ismail A, Budkowska M, Salata D, et al. Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs). *Leukemia.* 2014;28(11):2148-54.
69. Ratajczak MZ, Adamiak M, Kucia M, Tse W, Ratajczak J, and Wiktor-Jedrzejczak W. The Emerging Link Between the Complement Cascade and Purinergic Signaling in Stress Hematopoiesis. *Front Immunol.* 2018;9:1295.
70. Ratajczak MZ, and Adamiak M. Membrane lipid rafts, master regulators of hematopoietic stem cell retention in bone marrow and their trafficking. *Leukemia.* 2015;29(7):1452-7.
71. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. *Nat Med.* 2013;19(12):1617-24.
72. Wilkinson AL, Barrett JW, and Slack RJ. Pharmacological characterisation of a tool alphavbeta1 integrin small molecule RGD-mimetic inhibitor. *Eur J Pharmacol.* 2019;842:239-47.


## Figures and Figure Legends




**Figure 1: Targeting VLA4 and CXCR2 to mobilize HSPCs.** (A-B) DBA2/J mice were treated with the VLA4 inhibitor firategrast (100 mg/kg, i.v.), the CXCR2 ligand tGro- $\beta$  (2.5 mg/kg, s.c.) or both agents immediately after each other. Blood was analyzed for WBCs (A) and CFU-Cs (B). Data represent the mean  $\pm$  SEM,  $n=5$ . \*\*\* $p < 0.001$ , \*\* $p < 0.01$ , compared to firategrast alone / compared to tGro- $\beta$  alone. (C) Molecular structures. (D) G2-ALL cells were treated in duplicate with the VLA4 inhibitors shown in C. Percent inhibition of VCAM1 binding as compared to untreated samples. Data represent the mean  $\pm$  SEM of a single experiment representative of three experiments. (E) DBA2/J mice were injected with tGro- $\beta$  (2.5 mg/kg, s.c.), a VLA4 antagonist (3 mg/kg, i.v., for Bios192, CWHM-823 and 842; 100 mg/kg, i.v., for firategrast) or their combination. Controls received vehicle only. Numbers of circulating CFU-C and LSK were analyzed 0.5 hrs after the injection(s). Data represent the mean  $\pm$  SEM,  $n=8-10$ . \*\*\* $p < 0.001$ , \*\* $p < 0.01$ , \* $p < 0.05$ , compared to tGro- $\beta$  alone / compared to VLA4 antagonist alone. (F) HSPC mobilization in CXCR2 knockout mice using the CXCR2 ligands CXCL1, CXCL2 (tGro- $\beta$ ), and CXCL8 and the VLA4 antagonist CWHM-823 as well as their combinations was compared to wildtype BALB/cJ. Blood CFU-C numbers were analysed at baseline, 15 min after injection of CXCR2 ligands (s.c., 1 mg/kg of CXCL1 and CXCL8, 2 mg/kg of tGro- $\beta$ ), 1 hr after injection of CWHM-823 (s.c., 3 mg/kg) and 30 min after the combined treatment (s.c. injection of each ligand together with CWHM-823 at same doses as single treatments). Data represent the mean  $\pm$  SEM,  $n=4-26$  in mobilized groups,  $n=5-178$  in baseline groups. \*\*\* $p < 0.001$ , compared to CXCR2 agonist alone / compared to CWHM-823 alone. Statistical comparisons were made using linear mixed models in A & B and ANOVA in all others, followed by step-down Bonferroni adjustment for multiple comparisons.




**Figure 2: Properties of mobilized HSPCs.** (A) Schema for analyzing competitive repopulating capacity. Blood (10  $\mu$ L) from CD45.1+ donors (BALB/cJ, n=2-3) mobilized with G-CSF (9 doses q12h, 100 g/kg per dose), tGro- $\beta$  (2.5 mg/kg, 15 min after s.c. injection), VLA4 antagonists fintregrest (100 mg/kg, 1 hr after s.c. injection) and CWHM-823 (3 mg/kg, 1 hr after s.c. injection) or the combination of tGro- $\beta$  + VLA4 antagonist (dosed as indicated for single injections, 30 min after simultaneous injection) was mixed with CD45.2+ competitor BM cells (BALB/cJ, n=2 donors,  $2.5 \times 10^5$  cells per recipient) and transplanted into lethally irradiated primary CD45.2+ hosts (BALB/cJ, n=8-10 recipients). (B) Percent CD45.1+ donor cells within the CD45+CD3- compartment of blood was evaluated 20 weeks post-transplantation. Data represent the mean  $\pm$  SEM, n=8-10. \*\*\*p<0.001, \*p<0.05 compared to VLA4 antagonist alone/compared to tGro- $\beta$  alone. (C) BM from the primary recipients was harvested, pooled and transplanted into lethally irradiated secondary recipients (CD45.2+ BALB/cJ,  $2.5 \times 10^6$  per recipient). The percentage of donor derived cells in the blood of secondary recipients 18 weeks post-transplantation is shown. Data represent the mean  $\pm$  SEM, n=5 and are not significantly (n.s.) different. (D-F) LSK cells were sorted from the blood of DBA/2J mice mobilized with G-CSF (9 doses q12h, 100 g/kg per dose, n=3), AMD3100 (5 mg/kg, 1 hr post-injection, n=3), or CWHM-823+tGro- $\beta$  (3 mg/kg + 2.5 mg/kg, 30 min after simultaneous s.c. injection, n=3). LSKs from steady state BM were included as control. Total RNA from sorted cells was subjected to micro-array expression analysis. (D) Principal component analysis (PCA) of mRNA expression of different LSK species (E) Corresponding hierarchical clustering map. (F) Normalized expression values for the genes Nr4A1-3, n=3 samples (each pooled from up to 6 donors) per source/treatment group. Statistical comparisons were made using ANOVA, followed by step-down Bonferroni adjustment for multiple comparisons.




**Figure 3: Granulocytes are indispensable for tGro- induced mobilization. (A)** Testing of different sequences of injection. Two groups of BALB/cJ mice received pretreatment with PBS or tGro-β (2.5 mg/kg, s.c.) 15 min prior to the injection of CWHM-823 (3 mg/kg, s.c.). Accordingly, two other groups were pretreated with PBS or the VLA4 antagonist (3 mg/kg CWHM-823, s.c.) 45 min prior to tGro-β (2.5 mg/kg, s.c.) injection. A fifth group received a simultaneous injection of CWHM-823 + tGro-β at the indicated doses. At the timepoints 15 and 60 minutes after the administration of the second compound (or the simultaneous injection in the control group) circulating CFU-C numbers were measured. Each bar represents the mean±SEM, n=4-5. **(B-D)** For transient depletion of PB neutrophils mice were pretreated with an anti-Gr1 antibody in vivo (200 μg/mouse, i.v.) 36 hours prior to mobilization with tGro-β (2.5 mg/kg, s.c., timepoint 15 min), CWHM-823 (3.0 mg/kg, s.c., timepoint 60 min) or the combination of the two agents (doses same as for separate treatments, timepoint 30 min). Non-mobilized mice were used as controls (baseline). Moreover, all four conditions were analyzed in cohorts that had been pretreated with a control antibody (200 μg/mouse, i.v.). **(B)** Representative scatter plot analyses of unmobilized PB using flow cytometry, with granulocytes virtually absent in anti-Gr1 treated mice. **(C-D)** Numbers of circulating neutrophils **(C)** and CFU-C **(D)**. Each bar represents the mean±SEM, n=7-9. \*\*\*p<0.001, \*\*p<0.01, \*p<0.05. Statistical comparisons were made using ANOVA, followed by step-down Bonferroni adjustment for multiple comparisons. Logarithm transformation was performed for the data in **C & D**.



**Figure 4. CXCR2 expression in both the hematopoietic and non-hematopoietic (stroma) compartment contributes to tGro-β induced mobilization.** (A) Hematopoietic-specific CXCR2 KO mice were generated by transplanting lethally irradiated CD45.1+ recipients (BALB/cJ) with CD45.2+ BM cells isolated from CXCR2 KO mice (BALB/c,  $1 \times 10^6$  cells per recipient,  $n=3$  BM donor mice). A control group was reconstituted with CD45.2+ wt BM cells (BALB/c,  $1 \times 10^6$  cells per recipient,  $n=3$  BM donor mice). Stromal specific KOs were generated by transplanting CD45.1+ wt BM cells (BALB/cJ,  $1 \times 10^6$  cells per recipient,  $n=3$  BM donors) into CXCR2 KO mice (CD45.2+). In the corresponding control group, wt CD45.2+ recipients were transplanted with the wt CD45.1+ BM graft. (B-D) Three months post-transplantation, circulating HSPC numbers (Lin-Kit+ cells) were assessed in the different recipients at baseline and following mobilization with CWHM823 alone (3 mg/kg, 1 hr after s.c. injection, B), tGro-β alone (2.5 mg/kg, 15 min after s.c. injection, C) and both agents combined (dosed as indicated for separate treatments, 30 min after simultaneous s.c. injection, D). Each bar represents the mean  $\pm$  SEM,  $n=4-5$ . (E) Lethally irradiated CXCR2<sup>fl</sup>Cdh5Cre+ hosts (C57BL/6 background, CD45.2+) were reconstituted with syngeneic wt CD45.1+ BM ( $3 \times 10^6$  cells per recipient) to generate endothelial cell (EC) specific KO recipients. In the control group CXCR2<sup>fl</sup>Cre+ and CXCR2<sup>fl</sup>Cre+ mice were used as recipients. Three months post-transplantation circulating HSPC (CFU-C) numbers were quantified at baseline and following mobilization with CWHM823 alone (3 mg/kg, 1 hr after s.c. injection), tGro-β alone (2.5 mg/kg, 15 min after s.c. injection) and both agents combined (dosed as indicated for separate treatment, 30 min after simultaneous s.c. injection). Each bar represents the mean  $\pm$  SEM,  $n=6$ . \*\*\* $p < 0.001$ , \*\* $p < 0.01$ , \* $p < 0.05$ . Statistical comparisons were made using ANOVA, followed by step-down Bonferroni adjustment for multiple comparisons. Logarithm transformation was performed for the data in D&E.



**Figure 5. Role of cell adhesion on mobilization. (A-C)** Mobilization in LFA1 (CD11a) and Mac1 (CD11b) knockout (KO) mice. CD11a and CD11b KO as well as wildtype C57BL/6J mice received an injection of PBS, tGro-β (2.5 mg/kg, s.c., timepoint 15 min), CWHM-823 (3.0 mg/kg, s.c., timepoint 60 min) or the two agents combined (dosed the same as for separate treatments, timepoint 30 min). Mobilization of WBC (A), neutrophils (NE, B) and CFU-C (C) was assessed. Each bar represents the mean ± SEM, n=4-8. \*\*\*p<0.001, \*\*p<0.01, \*p<0.05. Statistical comparisons were made using ANOVA, followed by step-down Bonferroni adjustment for multiple comparisons.



**Figure 6. Proposed mechanisms for targeting CXCR2 and VLA4 to mobilize hematopoietic stem cells.** (A-D) Schematic presentation of HSPC and mature hematopoietic cell (neutrophil, NE) localization in the BM relative to the vasculature. Adhesive interactions and cellular distribution are shown under steady state (A) compared to following mobilization with a CXCR2 agonist (B), VLA4 antagonist (C) and the combination of the two strategies (D). For detailed description see Discussion.